Equity Is Not Equal: A Comparative Study of How Equity Is Considered by NICE, ICER, CDA-AMC, and PBAC

Author(s)

Olivenca F, Moore AIG, Ramagopalan S, Pearson-Stuttard J
Lane Clark & Peacock, Health Analytics, London, UK

OBJECTIVES: Health technology assessment (HTA) agencies tend to lack clear guidelines as to how manufacturers should generate and present equity relevant data for consideration and how these bodies will incorporate equity in their decision making. As such the role of equity in decision making by HTA agencies remains unclear. This study aimed to examine how equity is currently integrated in the processes of four HTA bodies: NICE (England), ICER (USA), CDA-AMC (formerly CADTH, Canada) and PBAC (Australia).

METHODS: Health technology appraisals published by the four agencies between 2021 and 2024 were assessed for equity considerations and classified based on data used (quantitative or qualitative) and therapeutic area. The domain of equity raised and acknowledgment in the final recommendation was also examined.

RESULTS: The proportion of appraisals identifying an equity issue was 62% (53/85) for NICE, 100% (16/16) for ICER, 92% (12/13) for CDA-AMC and 49% (64/130) for PBAC. For specific interventions evaluated by at least two agencies, there was only 60% cross-agency alignment regarding the presence and category of equity issues. ICER had the highest percentage of appraisals incorporating a quantitative approach (37%), all through the inequality-adjusted Human Development Index. Of the appraisals identifying equity issues, the most frequent therapeutic area was oncology (28%). Overall, ethnicity was the most commonly identified domain followed by socioeconomic status and geographic considerations. The acknowledgment of equity in final appraisal guidance was generally limited, being referred to in only 14% (12/85) of NICE and 32% (41/130) of PBAC appraisals.

CONCLUSIONS: Equity considerations are currently not being systematically considered by major HTA agencies. Approaches vary substantially across the globe and established methods to quantify the equity impact of new technologies like distributional cost-effectiveness analysis are not being employed. A more comprehensive approach to consider equity during HTA is urgently required.

Conference/Value in Health Info

2024-11, ISPOR Europe 2024, Barcelona, Spain

Value in Health, Volume 27, Issue 12, S2 (December 2024)

Code

HTA104

Topic

Health Policy & Regulatory, Health Technology Assessment

Topic Subcategory

Decision & Deliberative Processes, Health Disparities & Equity

Disease

No Additional Disease & Conditions/Specialized Treatment Areas, Oncology

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×